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v-ErbA, an oncogenic derivative of the thyroid hormone receptor ␣ (TR␣) carried by the avian erythroblastosis virus, contains several alterations including fusion
of a portion of avian erythroblastosis virus Gag to its N
terminus, N- and C-terminal deletions, and 13 amino
acid substitutions. Nuclear export of v-ErbA occurs
through a CRM1-mediated pathway. In contrast, nuclear export of TR␣ and another isoform, TR␤, is CRM1independent. To determine which amino acid changes
in v-ErbA confer CRM1-dependent nuclear export, we
expressed a panel of green and yellow fluorescent protein-tagged mutant and chimeric proteins in mammalian cells. The sensitivity of subcellular trafficking of
these mutants to leptomycin B (LMB), a specific inhibitor of CRM1, was assessed by fluorescence microscopy.
Our data showed that a nuclear export sequence resides
within a 70-amino acid domain in the C-terminal portion
of the p10 region of Gag, and in vitro binding assays
demonstrated that Gag interacts directly with CRM1.
However, a panel of ligand-binding domain mutants of
v-ErbA lacking the Gag sequence exhibited greater nuclear localization in the presence of LMB, suggesting
that the various amino acid substitutions/deletions may
cause a conformation shift, unmasking an additional
CRM1-dependent nuclear export sequence. In contrast,
the altered DNA-binding domain of the oncoprotein did
not contribute to CRM1-dependent nuclear export. Heterokaryon experiments revealed that v-ErbA did not
undergo nucleocytoplasmic shuttling when the CRM1
export pathway was blocked by LMB treatment, suggesting that the ability to follow the export pathway
used by TR␣ has been lost by the oncoprotein during its
evolution. Our findings thus point to the intriguing possibility that acquisition of altered nuclear export capabilities contributes to the oncogenic properties of
v-ErbA.
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The v-erbA oncogene is transduced by the avian erythroblastosis virus (AEV)1 from the cellular c-erbA protooncogene encoding the thyroid hormone receptor ␣ (TR␣), a member of the
nuclear receptor superfamily (1). During the course of oncogene
activation, v-erbA was fused to an AEV gag sequence at its N
terminus. In addition, v-erbA acquired two small deletions in
the N and C termini and 13 amino acid substitutions interspersed throughout the DNA-binding domain, hinge region, and
ligand-binding domain (2, 3). Studies involving mutant forms of
the oncoprotein v-ErbA (also referred to as p75gag-v-erbA) have
illustrated the importance of these sequence alterations for its
oncogenic properties (4 –12). Although v-ErbA has retained the
capacity to bind corepressors (13, 14), it has lost hormone binding
and transactivation activity and has altered DNA binding
specificity (3, 15–22).
TR␣ exhibits a dual role as an activator or repressor of gene
transcription in response to thyroid hormone. In mammalian
and avian cancer cells v-ErbA acts, in part, as a transcriptional
repressor of TR␣. However, a number of reports have argued
against a simple dominant negative function for the oncoprotein (23, 24). Instead it has been proposed that v-ErbA contributes to tumor formation by interfering with the action of both
liganded and unliganded TR␣ (25). Most likely, v-ErbA interferes with TR␣-mediated transcription through multiple pathways, including a direct effect on TR␣ activity (7, 24, 26, 27),
dysregulation of the expression of other target genes by inappropriate activation of the transcription factor AP-1 (28 –30),
and repression of transcriptional activity of the receptors for
estrogen and retinoic acid (7, 20).
We are interested in understanding the molecular basis behind the oncogenic conversion of TR␣ into v-ErbA and the mode
of action of dominant negative transcription factors in general.
The exact mechanism for transcriptional repression by v-ErbA
has not yet been determined, but evidence points to competition for DNA binding sites and cofactors and formation of
inactive heterodimers (19). One relatively unexplored mode of
oncogenic action is the effect of altered subcellular localization.
Regulated nuclear localization of transcription factors can act
as a molecular switch to control transcription (31–33). Thus,
knowledge of the mechanisms regulating nuclear transport of
v-ErbA, in particular its nuclear export, may provide a deeper
understanding of its oncogenic activity.
v-ErbA exhibits differential subcellular localization and nuclear export from its cellular homolog TR␣. While TR␣ shuttles
rapidly between the nucleus and cytoplasm but is primarily

1
The abbreviations used are: AEV, avian erythroblastosis virus; aa,
amino acid(s); TR␣, thyroid hormone receptor ␣; TR␤, thyroid hormone
receptor ␤; LMB, leptomycin B; NES, nuclear export sequence; RSV,
Rous sarcoma virus; GFP, green fluorescent protein; YFP, yellow fluorescent protein; DAPI, 4⬘,6-diamidino-2-phenylindole; GST, glutathione
S-transferase; N, nuclear; C, cytoplasmic.
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v-ErbA Nuclear Export
localized to the nucleus, v-ErbA accumulates in both nuclear
and cytoplasmic compartments in the cell. Leptomycin B
(LMB), a specific inhibitor of the export receptor CRM1 (34),
blocks nuclear export of v-ErbA; LMB treatment results in
complete nuclear localization of v-ErbA, indicating that v-ErbA
follows a CRM1-dependent nuclear export pathway (35). In
contrast, nucleocytoplasmic shuttling of TR␣ is not blocked by
LMB, indicating that TR␣ exits the nucleus by a CRM1-independent export pathway (35).
To determine which amino acid changes in v-ErbA confer
CRM1-dependent nuclear export, we tested a panel of v-ErbA
mutants and chimeric proteins. Using transient transfection
assays, their subcellular trafficking was assessed for sensitivity to LMB. Our data showed that the Gag region of v-ErbA
interacts directly with CRM1 and mediates v-ErbA nuclear
export. More specifically, we showed that the nuclear export
sequence (NES) resides within a 70-amino acid domain in the
C-terminal portion of the p10 region of Gag. In contrast, the
altered DNA-binding domain of the oncoprotein did not contribute to CRM1-dependent nuclear export, whereas data suggested that the ligand-binding domain of v-ErbA may play
some role in mediating CRM1-dependent nuclear export. When
the CRM1 export pathway was blocked by LMB treatment,
nucleocytoplasmic shuttling of v-ErbA was inhibited, suggesting that the ability to follow the export pathway used by TR␣
has been lost by the oncoprotein during its evolution. Taken
together, our findings point to the intriguing possibility that
acquisition of altered nuclear export capabilities contributes to
the oncogenic properties of v-ErbA.
EXPERIMENTAL PROCEDURES

Plasmids—T7-V3 contains the coding region for a fusion protein
termed Gag-TR␣ comprised of TR␣ with the Gag sequence from v-ErbA
fused to amino acid 13 of TR␣, thereby deleting the first 12 amino acids
of TR␣ (22). pGEX-KG-v/c/v encodes v/c/v, a chimeric protein in which
the DNA-binding domain of v-ErbA was replaced by the DNA-binding
domain of TR␣ (21). In pRS-⌬Gag-v-ErbA the viral Gag sequence is
deleted, but it still possesses the N- and C-terminal deletions and the 13
point mutations that distinguish v-ErbA from TR␣ (36). The ⌬Gag-vErbA mutants (⌬H10, ⌬H11A, ⌬H11B, L353R, ⌬9heptad, ⌬20aa,
L360R, and D232A) have substitutions or deletions in regions thought
to be important in dimerization (36). For the construction of expression vectors for the viral Gag domain alone, the gag sequence was
isolated from the 5⬘ end of v-erbA through PCR amplification of that
region from a GFP-v-ErbA expression vector (35). Gag and v-erbA
mutant coding sequences were subcloned into pEGFP-C1 (Clontech).
In addition, the gag sequence from v-erbA was subcloned into
pGEM-4Z (Promega, Madison, WI) for in vitro translation assays.
Expression vectors for p53-GFP and GFP-TR␣ and for in vitro translation of TR␣ and v-ErbA were as described previously (35, 37).
GFP-TR␤ was constructed by subcloning the human TR␤ cDNA from
RSh-TR␤ (38) into pEGFP-C1. pET-His-CRM1-H, pGST-Ranwt, and
pGST-RanQ69L were used for bacterial overexpression of His-tagged
full-length human CRM1 (39), GST-tagged wild-type Ran and mutant
RanQ69L (35), respectively.
To construct YFP-tagged Gag-(1–70) and Gag NES, coding sequences
for the first 70 amino acids of Gag and the putative CRM1-dependent
NES in the C terminus of Gag (aa 174 –244), plus the addition of a stop
codon, were subcloned into pEYFP-C1 (Clontech) between the HindIII
and EcoRI restriction sites by PCR amplification of these regions from
GFP-v-ErbA. To construct YFP-RSVp10, the Rous sarcoma virus (RSV)
p10 sequence was synthesized by hybridizing two long synthetic oligonucleotides with a 25-bp overlap, the appropriate restriction sites, and
a stop codon and then completing the fragment by PCR. The PCR
product was subsequently purified from a 12% denaturing polyacrylamide gel, PCR-amplified, and subcloned into pEYFP-C1 between the
HindIII and EcoRI restriction sites. YFP-Gag⌬CRM1 and YFP-vErbA⌬CRM1 were constructed as follows. The v-ErbA⌬CRM1 fragment
was made by ligating PCR fragments coding for aa 1–177 and aa
239 – 640 obtained from expression vectors for GFP-Gag and GFP-vErbA, respectively, joined together at a KpnI restriction site. This
ligation product was subsequently PCR-amplified into v-ErbA⌬NES
and Gag⌬NES with the appropriate primers and then subcloned into
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pEYFP-C1 between the HindIII and EcoRI restriction sites. The identity of all constructs was confirmed by sequencing with an ABI 3100
Avant Automated DNA Sequencer (Applied Biosystems Inc., Foster
City, CA).
Transfection and LMB Treatment—Transient transfection assays
were performed exactly as described previously (35). NIH/3T3 cells
were treated with either 10 ng/ml LMB (either from M. Yoshida, University of Tokyo, Tokyo, Japan or from Sigma) or the same volume of
absolute EtOH or MeOH (vehicle control). In some trials, EtOH or
MeOH was omitted since we have observed no difference in the
distribution of GFP-tagged receptors between EtOH- or MeOHtreated and untreated controls. After a 5-h incubation, cells were
fixed as described previously (35) and mounted either in Vectashield
containing DAPI (Vector Laboratories, Inc., Burlingame, CA) or in
Vectashield after staining the DNA with 1 M TO-PRO-3 (Molecular
Probes, Eugene, OR). Nucleocytoplasmic distribution was analyzed
using an Olympus epifluorescence microscope and a Cooke SensiCam
high performance digital black and white camera or a Radiance 2100
laser scanning microscope system (Bio-Rad) mounted on a Nikon
Eclipse TE300 inverted microscope. Subsequently digital images
were pseudocolored using IPLab scientific imaging software
(Scanalytics, Fairfax, VA).
Analysis of Nucleocytoplasmic Distribution—Transfection experiments were carried out three times for each construct with ⬃100 cells
analyzed per trial. Scoring of cells was performed blindly without prior
knowledge of LMB treatment. Cells were categorized into four groups
based on qualitative assessment of subcellular distribution: whole cell
or cytoplasmic distribution (N ⱕ C), weak nuclear localization (N ⬎ C),
strong nuclear localization (N ⬎⬎ C), and complete nuclear localization
(all N). Log-linear analysis was used to determine the statistical significance of differences in subcellular distribution. Since the cell counts for
the deletion/substitution v-ErbA mutants contained multiple zeros in
classification categories, these data were compressed to two categories:
whole cell distribution and nuclear localization (including weak, strong,
and complete nuclear localization). Whenever possible, analysis was
carried out using both the four-category and two-category schemes, and
the results were compared.
Heterokaryon Assays—Heterokaryon assays were performed exactly
as described previously (35). NIH/3T3 cells were incubated in 10 ng/ml
LMB (or an equivalent volume of EtOH or MeOH as a control) in culture
medium containing 100 g/ml cycloheximide for 2.5 h before fusion with
HeLa cells. Following cell fusion, the cells were incubated in LMB (or an
equivalent volume of EtOH or MeOH) for 5–10 h at 37 °C. Fixation and
staining for DNA and actin were carried out as described previously
(35). For heterokaryon analysis, shuttling was indicated by the presence of GFP-tagged protein in both the transfected NIH/3T3 and untransfected HeLa nuclei.
Pull-down Assays—Direct interaction between CRM1 and either the
Gag domain from v-ErbA, v-ErbA, or TR␣ was examined by His pulldown assays. The His-CRM1 fusion protein was expressed in Escherichia coli BL21-Codon Plus (DE3)-RIL cells (Stratagene, La Jolla, CA).
After induction with 0.5 M isopropyl-1-thio-␤-D-galactopyranoside at
30 °C, bacterial cells were harvested and sonicated in B-PER® bacterial
protein extraction reagent (Pierce) supplemented with 500 g/ml lysozyme. His-CRM1 was purified using TALONTM metal affinity resin
(Clontech) according to the manufacturer’s instructions. The presence
of His-CRM1 in eluted samples was confirmed by 8% SDS-PAGE and
staining with Simply BlueTM SafeStain (Invitrogen). Radiolabeled
Gag, v-ErbA, and TR␣ were translated in vitro using the TNT-coupled
transcription/translation system (Promega) in the presence of
[35S]methionine (Amersham Biosciences) and T7, SP6, or T3 RNA
polymerase, respectively. Recombinant wild-type Ran and RanQ69L
were expressed in E. coli BL21 cells as GST fusion proteins. After
extraction in B-PER reagent, proteins were purified on glutathioneSepharose 4B beads (Amersham Biosciences) and charged with 20 M
GTP as described previously (35). Pull-down assays were carried out
in the presence of 20 M GTP and 140 ng of Ran or RanQ69L using the
ProfoundTM pull-down polyhistidine assay (Pierce) according to the
manufacturer’s instructions. Samples were analyzed by 10% SDSPAGE and fluorography as described previously (35). The presence of
Ran in the rabbit reticulocyte lysate from the TNT-coupled transcription/translation system was determined by Western blot analysis and
chemiluminescence detection (ECL, Amersham Biosciences) (35). The
blot of lysate samples was probed with anti-Ran (goat polyclonal
antibody, Santa Cruz Biotechnology, Inc.) at 1:100 and horseradish
peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology, Inc.) at 1:10,000.
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FIG. 1. Sequence differences between TR␣, v-ErbA, and mutants. The diagram depicts the major domains of TR␣ and variants consisting
of the truncated AEV Gag sequence, the N terminus, DNA-binding domain (DBD), hinge region (H), ligand-binding domain (LBD), and C terminus.
Amino acid substitutions in v-ErbA are indicated by residue number and standard amino acid abbreviation. Substitution of leucines are indicated
by open circles, while all other substitutions are indicated by filled black circles. For the synthetic v-ErbA mutants, deletions are indicated by
crossed rectangles, and substitutions are indicated by crossed circles. ⌬20aa, deletion of aa 218 –237; ⌬H10, deletion of helix 10 (aa 322–342);
⌬H11A, deletion of the region of helix 11 proximal to the ninth heptad (aa 346 –352); ⌬9heptad, deletion of the ninth heptad in helix 11 (aa
353–360); ⌬H11B, deletion of the region of helix 11 distal to the ninth heptad (aa 361–366); L353R, substitution of arginine by leucine at aa 353
in helix 11; L360R, substitution of leucine by arginine at aa 360 in helix 11; D232A; substitution of aspartic acid by alanine at aa 232.
RESULTS

Nuclear Export of the Gag Domain of v-ErbA Is Mediated by
CRM1—During the course of oncoprotein activation, v-ErbA
was fused to a portion of AEV Gag, acquired 13 interspersed
amino acid substitutions, and obtained small deletions in the N
and C termini (2, 3) (Fig. 1). Our prior studies have shown that
while TR␣ exits the nucleus by a CRM1-independent pathway,
the nuclear export of v-ErbA is CRM1-dependent (35). Thus, we
sought to ascertain which sequence differences between v-ErbA
and TR␣ conferred CRM1-dependent nuclear export.
The short residence time of TR␣ in the cytoplasm prohibits
study of nuclear export by conventional single cell analysis, but
in interspecies heterokaryon assays, the human nuclei act as a
trap for any TR␣ that appears, however transiently, in the
shared cytoplasm after export from mouse nuclei. Fig. 2A illustrates CRM1-independent nuclear export of TR␣ in a heterokaryon system (panels a– d) and extends our earlier findings to

another isoform of the thyroid hormone receptor, TR␤ (panels
e– h). Previously we have demonstrated that N-terminal fusion
with GFP is a valid probe for studying subcellular trafficking of
TR␣ and variants (35). NIH/3T3 (mouse) cells expressing
GFP-tagged TR␣ or TR␤ were fused with nonexpressing
HeLa (human) cells both in the presence and absence of LMB.
In both cases, TR␣ and TR␤ translocated from the mouse
nucleus to the human nucleus, indicating that their nuclear
export is CRM1-independent. To ensure that the LMB used
in our assays was chemically active, we tested the effect of
LMB on the shuttling ability of p53, a transcription factor
that follows a CRM1-mediated export pathway (40). As expected, nuclear export of p53 was sensitive to LMB; in the
presence of the drug, p53 remained localized to the mouse
nuclei (Fig. 2A, panels k and l), whereas in the absence of
LMB, p53-GFP accumulated in the human nuclei of the heterokaryons (panels i and j).

v-ErbA Nuclear Export
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FIG. 2. Nuclear export of the Gag domain of v-ErbA is mediated by CRM1. A, nucleocytoplasmic shuttling of TR␣, TR␤, and p53. For the
preparation of heterokaryons, NIH/3T3 (mouse) cells were transfected with expression vectors for GFP-tagged TR␣, TR␤, or p53 and incubated in
the presence or absence of LMB as indicated. Subsequently HeLa (human) cells were fused with the mouse cells to form heterokaryons in which
human and mouse nuclei share a common cytoplasm. Fused cells were incubated for 5 h in culture medium in the presence or absence of LMB.
Shuttling of GFP-tagged proteins was visualized by epifluorescence microscopy (panels a, c, e, g, i, and k). Human nuclei (white arrows) are
distinguished from mouse nuclei by differential coloration with Hoechst 33258 DNA stain and to some extent by their size (panels b, d, f, h,
j, and l). Approximately 10 heterokaryons were analyzed per experiment. Shuttling of TR␣ and TR␤ was not blocked by LMB. In contrast,
p53-GFP shuttling was inhibited. Heterokaryon formation was confirmed by Nomarsky microscopy; the Nomarsky image was merged with the
Hoechst-stained image (panel l). B, subcellular distribution of v-ErbA and Gag. NIH/3T3 cells were transfected with expression vectors for
GFP-tagged v-ErbA (panels a and c) and the Gag domain of v-ErbA on its own (panels e and g) as indicated. After treatment with LMB, cells
were fixed, stained with the DNA stain DAPI to reveal the nucleus (panels b, d, f, and h), and visualized by epifluorescence microscopy. C, bar
graph summarizing the effect of LMB on the subcellular distribution of v-ErbA (n ⫽ 300 cells for each treatment). D, bar graph summarizing
the effect of LMB on the subcellular distribution of Gag. White bars, vehicle control (⫺LMB); black bars, LMB treatment (⫹LMB) (n ⫽ 300
cells for each treatment). N ⱕ C, whole cell or cytoplasmic distribution; N ⬎ C, weak nuclear localization; N ⬎⬎ C, strong nuclear localization;
all N, complete nuclear localization.

To ascertain which sequence differences between v-ErbA and
TR␣ confer CRM1-dependent nuclear export, we first tested
whether the retroviral Gag domain of v-ErbA exhibits nuclear
export activity. In retroviruses, the complete Gag polyprotein
directs the assembly and release of virus particles from the
plasma membrane (41). Until recently, it was believed that Gag
proteins were targeted directly to the plasma membrane after

synthesis in the cytoplasm of the host cell; however, it has now
been shown that nuclear import and export of the Gag polyprotein are part of the RSV assembly pathway (42). For brevity, in
this report we use the term “Gag” to refer to the truncated Gag
domain present in v-ErbA as opposed to the complete Gag
polyprotein.
To characterize the subcellular localization of the AEV Gag
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FIG. 3. The Gag domain of v-ErbA interacts directly with CRM1 in vitro. A, purification of His-tagged CRM1 after overexpression in
bacteria. Lane 1, His-CRM1; lane 2, protein molecular mass standards. B, Gag and v-ErbA both interact with CRM1 in vitro. His pull-down assays
were performed using His-CRM1 and in vitro generated 35S-labeled TR␣, v-ErbA, or Gag (in rabbit reticulocyte lysate) in the presence or absence
of recombinant RanGTP or Ran Q69L as indicated. Lanes 1–9, flow-through fractions; lanes 10 –18, binding fractions (elutions). C, Ran is present
in rabbit reticulocyte lysate (RRL). Western blot analysis was performed on a sample of rabbit reticulocyte lysate (1 l). Blots were probed with
anti-Ran antibodies and visualized by chemiluminescence detection.

domain of v-ErbA, NIH/3T3 cells were transfected with an
expression vector encoding GFP-Gag on its own. In this case,
because Gag has a predominantly cytoplasmic localization, it is
possible to analyze nuclear export properties by conventional
single cell analysis instead of using the heterokaryon system.
Cells were scored qualitatively for the nucleocytoplasmic distribution of Gag using four categories: whole cell or cytoplasmic
distribution (predominantly cytoplasmic or evenly distributed
throughout the cytoplasm and nucleus, N ⱕ C), weak nuclear
localization (whole cell distribution but with a distinct accumulation in the nucleus, N ⬎ C), strong nuclear localization (predominantly nuclear with faint cytoplasmic fluorescence, N ⬎⬎
C), and complete nuclear localization (all N). Interestingly Gag
alone exhibited a subcellular distribution almost indistinguishable from that of v-ErbA (Fig. 2, B, compare panels a and e; C;
and D). The majority of cells (82%) exhibited a whole cell or
cytoplasmic distribution with a greater accumulation of Gag in
the cytoplasm; however, some cells (18%) showed weak nuclear
localization of Gag (Fig. 2D).
Since some truncated AEV Gag accumulated in the nucleus,
this suggested that it is capable of nuclear import either via a
signal-mediated pathway or by passive diffusion through the
nuclear pore complex. The predominantly cytoplasmic localization, however, also implies the ability to exit the nucleus. To
determine whether Gag follows a CRM1-dependent nuclear
export pathway, we tested the sensitivity of Gag to LMB.
Strikingly Gag showed marked sensitivity to LMB. Treatment
for 5 h with LMB resulted in a significant increase (p ⬍ 0.0001)
in nuclear retention of Gag; only 18% of the cells showed weak
nuclear localization of Gag in the absence of LMB compared
with 59% in the presence of LMB (Fig. 2, B, panel g, and D).
However, unlike v-ErbA in which 87% of the cells showed
nuclear accumulation in the presence of LMB (Fig. 2, B, panel
c, and C), Gag was not completely localized to the nucleus when
CRM1 was inhibited (Fig. 2, B, panel g, and D). The continued
presence of a cytoplasmic population of Gag (41% of cells) could
indicate that nuclear import of the GFP-tagged truncated viral
protein alone is less efficient than when it is fused to v-ErbA.
However, after 10-h treatment with LMB, there was no further
increase in the amount of Gag trapped in the nucleus (data not
shown), suggesting that the apparent differential sensitivity to
LMB between Gag alone and Gag fused with v-ErbA is not
simply a result of altered nuclear import kinetics but rather
due to changes in v-ErbA other than the Gag sequence. Alternatively, since GFP-Gag (⬇55 kDa) is, in principle, within the
size limits (less than 60 kDa) for passive diffusion through the

central channel of the nuclear pore complex (35), it is possible
that in the presence of LMB Gag passively diffuses in or out of
the nucleus to reach a more cytoplasmic distribution than
v-ErbA at steady state. Additional possible explanations are
that Gag uses the CRM1 pathway with altered affinity when
not fused to v-ErbA, or there is a second NES in Gag that is not
LMB-sensitive. Experiments are in progress to distinguish between these possibilities. In summary, these data reveal that
the truncated Gag domain of v-ErbA can both enter and exit
the cell nucleus and follows a CRM1-mediated nuclear export
pathway.
The Gag Domain of v-ErbA Interacts Directly with
CRM1—To demonstrate that the truncated AEV Gag sequence
that was fused to v-ErbA during viral transduction interacts
directly with CRM1, His pull-down assays were performed. A
bacterially expressed His-CRM1 fusion protein (Fig. 3A) was
incubated with either in vitro generated 35S-labeled truncated
Gag, v-ErbA, or TR␣ (in rabbit reticulocyte lysate), and the
flow-through and binding (elution) fractions were analyzed by
SDS-PAGE and fluorography (Fig. 3B). Gag (lanes 13–15) and
v-ErbA (lanes 10 –12) both interacted with CRM1. In contrast,
as expected, all input TR␣ was present in the flow-through
fraction (lanes 7–9); no TR␣ bound specifically to CRM1 (lanes
16 –18). Even when a greater amount of TR␣ was included in
the pull-down assay, there was still no TR␣ detectable in the
bound fraction (data not shown). Rabbit reticulocyte lysate is
routinely used as the source of cytosol to support Ran-dependent in vitro nuclear transport assays, thus implying the presence of a sufficient supply of Ran in the lysate for specific
interaction of CRM1 with cargo. The presence of Ran in the
rabbit reticulocyte lysate was confirmed by Western blot analysis (Fig. 3C). Not surprisingly, the addition of exogenous wildtype Ran charged with GTP or mutant RanQ69L, which binds
GTP but resists hydrolysis, had no effect on the interaction of
Gag and v-ErbA with CRM1.
Fusion of Gag with TR␣ Confers Partial CRM1-dependent
Nuclear Export—To further characterize the effect of the truncated AEV Gag domain on the subcellular localization and
transport of v-ErbA, NIH/3T3 cells were transfected with a
GFP-tagged chimeric fusion protein of TR␣ and the Gag sequence from v-ErbA, termed Gag-TR␣ (Fig. 1). Cells were
scored for nucleocytoplasmic distribution according to the four
categories described earlier. Interestingly Gag-TR␣ exhibited a
subcellular localization distinct from that of both TR␣ (Fig. 4A)
and v-ErbA (Fig. 2B). Unlike TR␣, Gag-TR␣ was not completely
localized to the nucleus; 49% of cells exhibited a whole cell
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FIG. 4. Fusion of Gag with TR␣ confers partial CRM1-dependent nuclear
export on the receptor, while the nuclear export of ⌬Gag-v-ErbA is not
sensitive to LMB. A, the subcellular distribution of TR␣, Gag-TR␣, and ⌬Gag-vErbA. NIH/3T3 cells were transfected
with expression vectors for GFP-tagged
TR␣ (panels a– d) Gag-TR␣ (panels e– h),
or ⌬Gag-v-ErbA (panels i and j) as indicated. After treatment with LMB, cells
were fixed, stained with DAPI to reveal
the nucleus (panels b, d, f, h, j, and l), and
visualized by epifluorescence microscopy.
B, bar graph summarizing the effect of
LMB on the subcellular distribution of
Gag-TR␣. C, bar graph summarizing the
effect of LMB on the subcellular distribution of ⌬Gag-v-ErbA. White bars, vehicle
control (⫺LMB); black bars, LMB treatment (⫹LMB) (n ⫽ 300 cells for each
treatment). N ⱕ C, whole cell or cytoplasmic distribution; N ⬎ C, weak nuclear
localization; N ⬎⬎ C, strong nuclear localization; all N, complete nuclear
localization.

distribution (Fig. 4A, compare panel a with panel e). Further, in
contrast to v-ErbA, Gag-TR␣ did not exhibit a predominantly
whole cell or cytoplasmic distribution since 51% of cells expressing Gag-TR␣ showed weak to complete nuclear localization (compare Fig. 2B, panel a, with Fig. 4A, panel e). These
hybrid characteristics of Gag-TR␣ correlate well with previously identified functional properties of the chimeric protein.
Liganded Gag-TR␣ and TR␣ can both overcome v-ErbA repression of the erythroid carbonic anhydrase II gene in erythroid
progenitors and enhance transcription (43), but Gag-TR␣ subsequently causes aberrant differentiation (4).
To determine whether the truncated Gag sequence alone is
sufficient to mediate CRM1-dependent nuclear export of a chimeric protein, we tested the sensitivity of Gag-TR␣ to LMB.
Treatment for 5–10 h with LMB caused a significant difference
(p ⬍ 0.0001) in the subcellular localization of Gag-TR␣ with a
shift toward greater nuclear accumulation; 68% of cells showed
weak to complete nuclear localization in the presence of LMB
compared with 51% in the absence of LMB (Fig. 4, A, panel g,
and B). These data suggest that the AEV Gag sequence alone is

sufficient to confer partial CRM1 dependence on the fusion
protein Gag-TR␣.
To further clarify the influence of the viral Gag domain on
the nuclear export of v-ErbA, NIH/3T3 cells were transfected
with a v-ErbA mutant with a deletion of the Gag sequence,
⌬Gag-v-ErbA (Fig. 1), and scored for nucleocytoplasmic distribution. The subcellular localization of ⌬Gag-v-ErbA was different from that of both TR␣ and v-ErbA (compare Fig. 4A, panel
a, and Fig. 2B, panel a, with Fig. 4A, panel i). ⌬Gag-v-ErbA was
mostly retained in the nucleus with the majority of cells (89%)
exhibiting weak to complete nuclear localization (Fig. 4, A
and C).
To determine whether nuclear export of v-ErbA is CRM1-dependent in the absence of Gag, we tested the sensitivity of
⌬Gag-v-ErbA to LMB. Treatment with LMB had no apparent
effect on the subcellular distribution of ⌬Gag-v-ErbA; in both
the presence and absence of LMB, 89% of cells exhibited weak
to complete nuclear localization of the mutant protein (Fig. 4, A
and C). These data provide further evidence that the AEV Gag
sequence directs nuclear export of v-ErbA.
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FIG. 5. The truncated portion of the Gag polypeptide fused with v-ErbA includes the p10 sequence, which has a conserved NES.
A sequence comparison of RSV Gag (p10) and the v-ErbA Gag domain is depicted. Large, bold letters indicate the RSV region with NES-like
properties.

An NES Resides in the p10 Region of AEV Gag—When AEV
acquired c-erbA, the gene sequence was inserted at the viral
locus encoding the Gag polyprotein. As a result of this insertion, a portion of the gag gene sequence was fused with the
c-erbA sequence, while additional gag coding sequences were
displaced downstream (44, 45). Sequence comparison between
the portion of the AEV gag sequence that is fused with v-erbA
and the complete coding region for the Gag polyprotein of RSV
reveals extensive sequence homology (Fig. 5). After budding,
the RSV Gag polyprotein precursor is proteolytically cleaved
into the structural proteins MA, p2a, p2b, p10, CA, NC, and PR
(42). Of particular interest, the viral sequence fused with vErbA comprises the portion of Gag known as the p10 region,
which includes a sequence demonstrated to have NES-like
properties in RSV (42) (Fig. 5). The CRM1 nuclear export
receptor recognizes leucine-rich NESs, originally identified in
the human immunodeficiency virus, type 1 Rev protein and the
protein kinase A inhibitor (46 – 48). A cluster of leucine-rich
hydrophobic residues in the second half of RSV p10 is thought
likely to confer the NES properties (42).
To test whether a CRM1-dependent NES was embedded in
the p10 region in AEV Gag, we constructed a series of expression vectors for fusion proteins. We fused to YFP the C-terminal portion of the p10 region from AEV Gag containing the
putative NES (YFP-Gag NES). In addition, we fused a highly
hydrophobic 70-amino acid region from the N terminus of Gag
(YFP-Gag-(1–70)) to YFP to serve as a negative control and the
RSV p10 domain (YFP-RSV p10) for a positive control (Fig. 6A).
Cells were scored for nucleocytoplasmic distribution in the
presence or absence of LMB, according to the categories previously described, except for “weak” and “strong nuclear,” which
were combined into one category (N ⬎ C). As predicted,
treatment with LMB had no apparent effect on the subcellular distribution of YFP or YFP-Gag-(1–70). In both the absence and presence of LMB, ⬃68% of cells expressing YFP
alone and 47% of cells expressing YFP-Gag-(1–70) showed a
weak nuclear localization (Fig. 6, B, panels a– d, and C),
suggesting that these small proteins are able to freely diffuse
throughout the cell and that their nuclear export is CRM1independent. Interestingly YFP-Gag-(1–70) did not have exactly the same distribution as YFP; not only did this fusion
protein exhibit a greater whole cell distribution, but it often
formed foci in the cytoplasm. Although the nature of these
foci remains to be determined, it is tempting to speculate that
the N-terminal 70 amino acids of AEV Gag may mediate
formation of these cytoplasmic foci also characteristic of vErbA. In addition, sequestration in the cytoplasm could slow
diffusion, thereby causing YFP-Gag-(1–70) to have a greater
cytoplasmic distribution compared with untagged YFP at
steady state.
In striking contrast to YFP and YFP-Gag-(1–70), in the absence of LMB the putative NES-bearing fusion proteins YFPRSV p10 and YFP-Gag NES were predominantly localized to
the cytoplasm (Fig. 6, B, panels e– h, and C) in ⬃70% of cells.
Addition of the CRM1 inhibitor resulted in a significant increase in their nuclear retention (p ⬍ 0.0001), suggesting that
the viral sequences confer CRM1-dependent nuclear export on

YFP. In the presence of LMB, both YFP-RSV p10 and YFP-Gag
NES showed a distribution similar to that of untagged YFP
with nearly 70% of cells exhibiting a weak or strong nuclear
localization (N ⬎ C). The continued presence of a cytoplasmic
population is most likely due to the small size of these constructs (⬍40 kDa), which would, in principle, allow their diffusion through the central channel of the nuclear pore complex
(Fig. 6, A; B, panels f and h; and C). Taken together, these data
provide strong evidence that the p10 region of AEV Gag contains an NES that is sufficient to mediate CRM1-dependent
nuclear export of a heterologous protein.
The p10 Domain of AEV Gag Mediates CRM1-dependent
Export of Gag and v-ErbA—To confirm that the p10 domain of
AEV Gag is necessary for CRM1-dependent nuclear export of
Gag and v-ErbA, we generated two deletion constructs, YFPGag⌬NES and YFP-v-ErbA⌬NES (Fig. 6A), which lack the
putative NES-bearing C-terminal portion of the AEV p10 region, and compared their subcellular distribution patterns with
those of YFP-Gag, YFP-v-ErbA, and YFP-⌬Gag-v-ErbA (see
also Fig. 4 for GFP-⌬Gag-v-ErbA). In the absence of LMB,
YFP-Gag⌬NES and YFP-v-ErbA⌬NES, like YFP-⌬Gag-vErbA, were significantly (p ⬍ 0.0001) more nuclear than YFPGag and YFP-v-ErbA in their subcellular distribution with only
10 –20% of cells showing a cytoplasmic localization (Fig. 6, B,
panels i, k, m, o, and q, and C). Addition of LMB resulted in a
significant increase in the nuclear retention of both YFP-Gag
and YFP-v-ErbA (p ⬍ 0.0001) with a 4 –5-fold increase of the
number of cells showing strong or complete nuclear localization
(Fig. 6, A, panels i and j and panels m and n, and C). In sharp
contrast, the subcellular distribution of the corresponding deletion constructs, YFP-Gag⌬NES, YFP-v-ErbA⌬NES, and
YFP-⌬Gag-v-ErbA, remained unaltered in the presence of LMB
(Fig. 6, B, panels k, l, and o–r, and C), demonstrating that when
the C-terminal portion or the entire Gag domain is deleted
these constructs are no longer LMB-sensitive. Interestingly
YFP-v-ErbA⌬NES also showed an altered nuclear distribution,
forming nuclear foci similar to those observed in v/c/v (described below) as well as forming cytoplasmic foci similar to
those characteristic of v-ErbA (Fig. 6B, panels m–p). Taken
together our data provide strong evidence that the p10 region of
AEV Gag (Fig. 5) contains an NES that is necessary and sufficient for CRM1-mediated nuclear export.
Effect of Amino Acid Substitutions in the Ligand-binding
Domain of v-ErbA on CRM1-mediated Nuclear Export—Since
the truncated AEV Gag sequence alone and Gag fused with
v-ErbA have differential sensitivity to LMB, we sought to ascertain whether additional sequence changes in v-ErbA contribute to its ability to exit the nucleus by a CRM1-mediated
pathway. NIH/3T3 cells were transfected separately with eight
different GFP-tagged ⌬Gag-v-ErbA mutants with deletions or
substitutions in the ligand-binding domain (Fig. 1) and scored for
nucleocytoplasmic distribution according to the four categories
described previously. All of the deletion/substitution mutants of
⌬Gag-v-ErbA (⌬20aa, ⌬H10, ⌬H11A, ⌬9heptad, ⌬H11B, L353R,
L360R, and D232A) exhibited on average 89% whole cell or
cytoplasmic distribution with the remaining cells showing weak
to strong nuclear localization. Data are summarized in Fig. 7.
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FIG. 6. The p10 region in AEV Gag mediates CRM1-dependent nuclear export of Gag and v-ErbA. A, the diagram depicts the various
YFP constructs used to identify the p10 region of Gag as a CRM1-dependent NES. Dashed lines indicate the approximate molecular mass cut-off
(60 kDa) for passive diffusion through the nuclear pore complex. B, representative examples of the subcellular distribution of the various YFP
constructs depicted in A. NIH/3T3 cells were transfected with the various constructs and left to shuttle for 6 h in the presence (⫹LMB) or absence
of LMB (⫺LMB) as indicated. Cells were fixed, stained with TO-PRO-3, and analyzed by confocal laser scanning microscopy. C, graph summarizing
the effect of LMB on the various constructs depicted in A and imaged in B. White bars, vehicle control (⫺LMB); black bars, LMB treatment (⫹LMB).
Three replicate experiments were performed with at least 100 cells scored per replicate. N ⱕ C, whole cell or cytoplasmic distribution; N ⬎ C, weak
or strong nuclear localization; All N, complete nuclear localization.
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FIG. 7. The effect of LMB on the subcellular localization of v-ErbA ligand-binding domain mutants. NIH/3T3 cells were transfected
with expression vectors for GFP-tagged ligand-binding domain mutants. The panel of v-ErbA deletion/substitution mutants (lacking the Gag
sequence) is depicted in Fig. 1. After treatment with LMB, cells were fixed, stained with DAPI to reveal the nucleus, and visualized by
epifluorescence microscopy. For each v-ErbA mutant, a total of 300 cells was scored for nucleocytoplasmic distribution. The bar graphs summarize
the effect of LMB on the various constructs. White bars, vehicle control (⫺LMB); black bars, LMB treatment (⫹LMB). N ⱕ C, whole cell or
cytoplasmic distribution; N ⬎ C, weak nuclear localization; N ⬎⬎ C, strong nuclear localization (there were no cells with complete nuclear
localization). Statistically significant results (p ⬍ 0.0001) are indicated.

Surprisingly treatment with LMB significantly altered the
distribution of six of the ⌬Gag-v-ErbA mutants (p ⬍ 0.0001 for
⌬20aa, ⌬H10, ⌬H11A, ⌬9heptad, ⌬H11B, and L353R; Fig. 7);
on average, there was a 3-fold shift toward greater nuclear
retention, although the majority of cells (67%) still exhibited a
cytoplasmic or whole cell distribution. A more modest, 2-fold
increase in retention was observed for D232A (p ⫽ 0.0014; Fig.
7). Only L360R did not exhibit greater nuclear retention in the
presence of LMB, 23 and 21% of cells exhibiting a weak nuclear
localization in the presence and absence of LMB, respectively.
In summary, these data suggest that the ligand-binding domain of v-ErbA may influence interaction of the oncoprotein
with CRM1.
The Altered DNA-binding Domain of v-ErbA Does Not Contribute to CRM1-dependent Nuclear Export—A recent report
suggests that TR␣, which lacks a leucine-rich NES for CRM1,
may contain an NES in a 15-amino acid sequence located
between the two zinc fingers of its DNA-binding domain (49).
This NES domain is conserved in the nuclear receptor superfamily and is thought to interact directly with the Ca2⫹-binding
protein calreticulin, a recently characterized nuclear export
receptor (50). The DNA-binding domain of v-ErbA has sustained two amino acid changes compared with TR␣ (Fig. 1). To
determine whether the altered DNA-binding domain of v-ErbA
plays a role in conferring CRM1-dependent nuclear export,
v/c/v, a chimeric fusion protein in which the DNA-binding domain of v-ErbA was replaced with the DNA-binding domain of
TR␣, was analyzed (Fig. 1). NIH/3T3 cells were transfected
with GFP-v/c/v and scored for nucleocytoplasmic distribution
according to the four categories described previously. v/c/v
showed a diversity of subcellular distributions (Fig. 8, A and B),
including entirely cytoplasmic (panel a), weak nuclear (panel
b), strong nuclear (panel c), and complete nuclear localization
(panel d). In cells with complete nuclear localization, v/c/v
showed either a diffuse distribution (Fig. 8A, panel d, nucleus
with no arrow) or localization to bright foci (panel d, nuclei with
an arrow). Similarly cytoplasmically localized v/c/v either
showed a diffuse distribution (not shown) or localization to
bright foci (panels a– c). The nature of these foci remains to be
determined.
To determine whether nuclear export of v-ErbA remains
CRM1-dependent in the presence of the TR␣ NES, we tested
the sensitivity of v/c/v to LMB. Treatment with LMB signifi-

cantly altered the subcellular distribution of v/c/v (p ⬍ 0.0001).
In the presence of LMB, v/c/v localized predominantly to the
nucleus (Fig. 8B). In contrast, in the absence of LMB, 38% of
v/c/v showed a whole cell or cytoplasmic distribution (Fig. 8B).
These findings suggest that the CRM1-dependent NES within
the AEV Gag p10 domain is dominant to the TR␣ CRM1independent NES.
When the Gag sequence was deleted, the distribution of
⌬Gag-v/c/v shifted to a more nuclear distribution with no cells
showing a whole cell or cytoplasmic distribution (Fig. 8C).
Treatment with LMB did not significantly alter the subcellular
distribution of ⌬Gag-v/c/v (p ⫽ 0.0088). In the presence of LMB,
68% of cells showed strong to complete nuclear localization of
⌬Gag-v/c/v compared with 57% in the absence of LMB (Fig. 8C).
These data provide further evidence of the critical importance
of the AEV Gag domain in mediating v-ErbA CRM1-dependent
nuclear export and cytoplasmic localization.
v-ErbA Does Not Undergo Nucleocytoplasmic Shuttling
When the CRM1 Export Pathway Is Blocked—In the presence of
LMB, v-ErbA appears to be entirely trapped in the nucleus,
suggesting that the oncoprotein solely uses the CRM1-mediated nuclear export pathway. However, if v-ErbA was, in fact,
undergoing rapid nucleocytoplasmic shuttling, this would not
be apparent in a single cell transfection assay. Therefore, to
determine whether v-ErbA still undergoes rapid nucleocytoplasmic shuttling in the presence of LMB, heterokaryon assays
were performed. In the majority of cells v-ErbA has a predominantly cytoplasmic distribution, thus in the absence of LMB
most heterokaryons showed both cytoplasmic and nuclear fluorescence. Accordingly the presence of v-ErbA in the untransfected human nuclei could represent import of a cytoplasmic
population rather than shuttling out of the mouse nucleus and
into the human nucleus. In those few cells in which GFP-vErbA was predominantly nuclear, however, v-ErbA still accumulated in the untransfected human nuclei (Fig. 9, panel a).
Importantly, in heterokaryons containing LMB-treated,
mouse nuclei transfected with GFP-v-ErbA and untransfected human nuclei, only the original transfected mouse
nucleus showed an accumulation of v-ErbA (Fig. 9, panel c).
Moreover v-ErbA did not accumulate in the untransfected
human nuclei even when the heterokaryons were incubated
for the maximum time possible before cell division (⬇10 h),
indicating that a lack of shuttling did not simply represent
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FIG. 8. The altered DNA-binding domain of v-ErbA does not contribute to
CRM1-dependent nuclear export. A,
subcellular distribution of v/c/v. NIH/3T3
cells were transfected with an expression
vector for GFP-tagged v/c/v (panels a– d).
Cells were fixed, stained with DAPI to
reveal the nucleus (panels e– h), and visualized by epifluorescence microscopy.
White arrows point to nuclei with foci. B,
bar graph summarizing the effect of LMB
on the subcellular distribution of v/c/v
(n ⫽ 879 cells). C, bar graph summarizing
the effect of LMB on the subcellular distribution of ⌬Gag-v/c/v (n ⫽ 698 cells).
White bars, vehicle control (⫺LMB); black
bars, LMB treatment (⫹LMB). N ⱕ C,
whole cell or cytoplasmic distribution;
N ⬎ C, weak nuclear localization; N ⬎⬎ C,
strong nuclear localization; all N, complete nuclear localization.

slower nucleocytoplasmic transport kinetics. These findings
demonstrate that v-ErbA does not shuttle between the nucleus and the cytoplasm when the CRM1 pathway is blocked,
suggesting that the ability to follow the export pathway used
by TR␣ has been lost by the oncoprotein v-ErbA during its
evolution.
To further test this model for oncogenic loss of the ability to
follow the TR␣ export pathway, we analyzed the nucleocytoplasmic shuttling properties of v/c/v. Heterokaryons were
formed by the fusion of LMB-treated or untreated transfected
mouse cells with untransfected human cells. In the absence of
LMB, v/c/v was found in both mouse and human nuclei (Fig. 9,
panel e), although as noted above for v-ErbA, this could be due
to import of a cytoplasmic population and not “shuttling” per se.
Interestingly, despite having the DNA-binding domain containing the TR␣ putative NES, Gag-v/c/v did not shuttle when
CRM1 was blocked by treatment with LMB (Fig. 9, panel g).
These data provide further evidence that the oncoprotein has
lost the ability to bind the TR␣ export receptor due to fusion
with Gag and possibly due to other sequence and conformational changes. This further confirms that the altered DNAbinding domain of the oncoprotein does not play an essential
role in mediating v-ErbA export.
DISCUSSION

Acquisition of a CRM1-dependent NES by v-ErbA—v-erbA,
an oncogenic derivative of a TR␣ gene carried by AEV, influences the transformation capabilities of the virus through interruption of the tightly regulated balance between host cell

proliferation and differentiation. The oncogenic effects of vErbA result, in part, from direct interference with TR␣mediated gene transcription. Here we present findings suggesting that, in addition, the altered subcellular localization
of v-ErbA plays a crucial role in its oncogenic properties.
While the oncoprotein v-ErbA exits the nucleus by a CRM1dependent pathway, its cellular homolog TR␣ follows a
CRM1-independent nuclear export pathway (35). In addition,
we show here that another isoform of the thyroid hormone
receptor, TR␤, also uses a CRM1-independent nuclear export
pathway. A recent report states that TR␤ export occurs by a
CRM1-mediated pathway (51). Since the data were not
shown, we cannot address possible reasons for this apparent
discrepancy.
The fusion of a portion of the AEV Gag sequence, including
the p10 domain, to the N terminus of v-ErbA allows the oncoprotein to interact directly with CRM1 and confers its CRM1mediated export. In addition, this finding raises the important
point that nuclear import and export of the Gag polypeptide
may be of importance for AEV assembly (42). The region that is
homologous to the RSV sequence with NES-like properties and
causes the CRM1-mediated export of v-ErbA closely resembles
the previously identified consensus sequence for the CRM1-dependent NES (48, 52) and therefore should give a better understanding of the sequence requirements for interaction of an
NES with CRM1. As a result of these altered export characteristics, the subcellular distribution of v-ErbA has shifted from
the predominantly nuclear localization of its cellular homolog
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FIG. 9. Nucleocytoplasmic shuttling of v-ErbA is CRM1-dependent. v-ErbA does not undergo shuttling when the CRM1 export pathway
is blocked. Similarly shuttling of v/c/v, a chimeric protein in which the DNA-binding domain of v-ErbA is replaced by the DNA-binding domain of
TR␣, is also inhibited, indicating that the altered DNA-binding domain of the oncoprotein does not play an essential role in v-ErbA export.
Heterokaryon assays were performed as described (Fig. 2) using mouse cells expressing GFP-tagged v-ErbA (panels a– d) or v/c/v (panels e– h) in
the presence or absence of LMB as indicated. Panels b and f, Hoechst 33258 DNA stain. Panels d and h, Hoechst 33258 DNA stain overlaid with
rhodamine-phalloidin actin stain to visualize the borders of heterokaryons. Approximately 20 heterokaryons were analyzed per experiment with
several replicate experiments. White arrows indicate human nuclei.

to a more cytoplasmic distribution, thereby limiting access of
the oncoprotein to target genes.
Results presented here also suggest that while the truncated
Gag sequence, and particularly amino acid residues 178 –243 of
the p10 domain, is necessary for interaction with CRM1, other
sequence differences between v-ErbA and TR␣ may enhance
the ability of the oncoprotein to follow the CRM1-mediated
nuclear export pathway. The lack of complete nuclear localization of the Gag sequence alone in the presence of LMB, a
specific inhibitor of CRM1, suggests that nuclear import of
truncated Gag may be inefficient. This result correlates with
the finding that nuclear localization of the RSV complete Gag
polypeptide is transient (42). Furthermore the lack of complete
nuclear localization of Gag-TR␣ in cells treated with LMB
suggests that the chimeric receptor does not use this CRM1mediated export pathway exclusively. It is likely that the Gag
sequence allows Gag-TR␣ to follow the CRM1-dependent export pathway in addition to using the export pathway utilized
by TR␣. This interpretation is consistent with the proposed
location of the TR␣ NES in its DNA-binding domain (49), a
sequence that is unaltered in the Gag-TR␣ fusion protein.
However, when the DNA-binding domain of v-ErbA was replaced with the DNA-binding domain of TR␣, this chimeric
protein (v/c/v) was not able to follow a CRM1-independent
export pathway, suggesting that when fused with v-ErbA other
sequence and conformational changes alter the ability to bind
to the export receptor and confer dominant properties on the
Gag NES. Finally blocking the CRM1 export pathway inhibited
nucleocytoplasmic shuttling of v-ErbA, suggesting that the oncoprotein can no longer use the CRM1-independent nuclear
export pathway utilized by TR␣ and that the CRM1-dependent
nuclear export pathway is the sole export pathway used by
v-ErbA.
Does the Ligand-binding Domain of v-ErbA Play a Role in
CRM1-dependent Nuclear Export?—The importance of the ligand-binding domain is illustrated by the nuclear export properties of ⌬Gag v-ErbA mutants, which contain modifications to
the ligand-binding domain. The nucleocytoplasmic distribution
of these deletion/substitution mutants was at first surprising.
Based on the distribution pattern of ⌬Gag-v-ErbA, we had
predicted a shift toward greater nuclear accumulation of these
mutants since they also lack the Gag sequence. However, considering the location of the mutations in the ligand-binding

domain, their whole cell distribution is consistent with current knowledge of the importance of this region for nuclear
import and/or retention (53), dimerization (36), and interference with TR␣-mediated transcription (4, 5). Further ⌬Gagv-ErbA showed no significant difference in subcellular distribution in the presence or absence of LMB. In contrast, seven
of the deletion/substitution mutants of ⌬Gag v-ErbA exhibited greater nuclear localization in the presence of LMB,
further suggesting that these mutants, after nuclear entry,
follow a CRM1-mediated export pathway. Still, because the
majority of cells show at least some cytoplasmic localization,
the possibility remains that these mutants may exit the
nucleus by another receptor-mediated export pathway when
CRM1 is blocked.
How might these v-ErbA ligand-binding domain mutants,
which also lack the Gag NES, follow the CRM1-dependent
export pathway? One possible explanation is that the various
amino acid deletions/substitutions cause a conformation shift,
unmasking an additional NES that is not exposed in ⌬Gag-vErbA. This model is supported by the export properties of the
mutant D232A; the single amino acid substitution probably
causes less of a conformation change than the large sequence
deletions in the other mutants, resulting in a weaker interaction with CRM1. Precedence for such a mechanism involving a
masked NES is illustrated by a number of proteins that undergo CRM1-dependent nuclear export, including INI1/hSNF5
(a component of the SWI/SNF complex chromatin remodeling
factor), the Ret finger protein, the p53 tumor suppressor, the
influenza NS1 protein, and adenoviral E4 protein (40, 54 –57).
Regulation of nuclear export through masking and unmasking
of NESs is thought to serve as yet another level of regulation of
gene expression.
The ninth heptad in the ligand-binding domain of v-ErbA is
leucine-rich, identifying it as a possible location for an additional NES that could enhance the altered nuclear export of
v-ErbA. This model is supported by the lack of CRM1 dependence of the substitution mutant L360R, which changes one of
these leucines to an arginine. In addition, mutants with modifications near the ninth heptad but not within the leucine-rich
region (⌬H11A, ⌬H11B, and L353R) exhibit the strongest
CRM1 dependence, suggesting that modifications close to the
ninth heptad may unmask the NES. However, the ninth heptad clearly does not contain the only additional motif with the
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potential to interact with CRM1. The deletion mutant ⌬9heptad, which lacks this region, still can follow the CRM1 nuclear export pathway. Moreover ⌬20aa and ⌬H10, which
modify regions further from the ninth heptad, also exhibit
CRM1 dependence. In addition to sequence alterations in the
ligand-binding domain, it is possible that amino acid substitutions in the hinge region, which include changes to leucines
(Fig. 1), act to further enhance interaction of the oncoprotein
with CRM1.
In summary, these data suggest two possible mechanisms for
CRM1 dependence in addition to the interaction with the truncated AEV Gag sequence. Amino acid substitutions acquired
during the evolution of the oncoprotein could by themselves
constitute a weak NES through the addition of leucines or
other hydrophobic amino acids, or these mutations could cause
a conformation shift that indirectly results in stronger interaction of the Gag NES with CRM1.
Implications for the Oncogenesis and Dominant Negative
Activity of v-ErbA—The shift toward a more cytoplasmic distribution of v-ErbA, which appears to be a direct result of
fusion with a viral NES, has implications for the mode of action
of v-ErbA. Prior studies provide evidence for a role of competition over DNA binding sites and cofactors and formation of
inactive heterodimers in oncoprotein repression of TR␣-mediated transcription (19). We propose that, in addition, the acquisition of altered nuclear export activity by the oncoprotein
v-ErbA may be a factor in its oncogenesis and suggest that
altered subcellular localization provides yet another mode of
action for dominant negative transcription factors in general.
Evidence from other studies further supports the role of
altered nuclear export in oncogenesis. For example, mislocalization of INI1/hSNF5 blocks its normal tumor suppression
function (54), p53 is hyperactively exported from the nucleus in
some transformed cells (40), and ectopic expression of the hepatitis B virus X protein sequesters CRM1 in the cytoplasm,
suggesting that the inactivation of the CRM1-mediated pathway may be an early step during viral hepatitis-mediated
liver carcinogenesis (58). The acquired use of CRM1mediated nuclear export by v-ErbA results in its mislocalization to the cytoplasm, which may affect gene expression directly or indirectly. It is known that overexpression of v-ErbA
is required for its oncogenic function (59). Since v-ErbA may
need to enter the nucleus to exert its dominant negative
activity, if most remains cytoplasmic, then overexpression
would be required to increase that amount available to interact or compete with TR␣.
In summary, our study demonstrates that CRM1-dependent
nuclear export of v-ErbA is primarily mediated by an NES
within a 70-amino acid region in the C terminus of the AEV
Gag p10 sequence and points to the possibility that amino acid
changes in other regions of v-ErbA play a cryptic role in CRM1mediated nuclear export. Further analysis is necessary to more
precisely clarify the involvement of these and other domains in
CRM1-dependent nuclear export. Taken together our findings
suggest that fusion of the viral Gag sequence with v-ErbA was a
crucial step in the evolution of the properties of this oncoprotein.
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